Literature DB >> 15034544

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.

B Lemieux1, S Tartas, C Traulle, D Espinouse, C Thieblemont, F Bouafia, Q Alhusein, D Antal, G Salles, B Coiffier.   

Abstract

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15034544     DOI： 10.1038/sj.bmt.1704467

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  17 in total

1.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

Authors:  Kieron Dunleavy; Frances Hakim; Hyun Kyung Kim; John E Janik; Nicole Grant; Takayuki Nakayama; Therese White; George Wright; Larry Kwak; Ronald Gress; Giovanna Tosato; Wyndham H Wilson
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

Review 2.  Rituximab-associated neutropenia.

Authors:  Kieron Dunleavy; Kevin Tay; Wyndham H Wilson
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

3.  Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma.

Authors:  Kenji Fukuno; Hisashi Tsurumi; Nobuhiro Ando; Nobuhiro Kanemura; Hideko Goto; Shinobu Tanabashi; Kiyonao Okamoto; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

4.  Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.

Authors:  Yuji Hirai; Yusuke Ainoda; Takayo Shoji; Takahiro Fujita; Kentaro Yoshinaga; Masayuki Shiseki; Naoki Mori; Masanao Teramura; Kyoichi Totsuka; Toshiko Motoji
Journal:  Mycopathologia       Date:  2011-04-07       Impact factor: 2.574

5.  Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors:  Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

6.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

Authors:  Daniel Tesfa; Tobias Gelius; Birgitta Sander; Eva Kimby; Bengt Fadeel; Jan Palmblad; Hans Hägglund
Journal:  Med Oncol       Date:  2008-02-16       Impact factor: 3.064

Review 7.  Management of relapsed diffuse large B-cell lymphoma.

Authors:  Vaishalee Padgaonkar Kenkre; Sonali M Smith
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

8.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

Authors:  Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek
Journal:  Cytotherapy       Date:  2012-09-18       Impact factor: 5.414

9.  Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

Authors:  Paul M Barr; Pingfu Fu; Hillard M Lazarus; Nancy Horvath; Stanton L Gerson; Omer N Koc; Nizar J Bahlis; Michael R Snell; Afshin Dowlati; Brenda W Cooper
Journal:  Br J Haematol       Date:  2009-06-29       Impact factor: 6.998

10.  Late-onset neutropenia following rituximab treatment for rheumatologic conditions.

Authors:  Gabriel S Breuer; Michael Ehrenfeld; Itzhak Rosner; Alexandra Balbir-Gurman; Devy Zisman; Shirley Oren; Daphna Paran
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.